All In Biotech

Drug Trial Radar · NCT01741155

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

34

Actual

Start

May 2013

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Dec 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

  • SPI-1620Drug

    SPI-1620 11 μg/m2 administered intravenously over one minute.

  • DocetaxelDrug

    Docetaxel: 75 mg/m2 administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR) of SPI-1620Time frame: Up to 2 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Oncology Hematology Care Inc.

    Cincinnati, Ohio

  • Tennessee Oncology PLLC

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas

  • Virginia Cancer Institute

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.